JP2022513507A5 - - Google Patents

Info

Publication number
JP2022513507A5
JP2022513507A5 JP2021535122A JP2021535122A JP2022513507A5 JP 2022513507 A5 JP2022513507 A5 JP 2022513507A5 JP 2021535122 A JP2021535122 A JP 2021535122A JP 2021535122 A JP2021535122 A JP 2021535122A JP 2022513507 A5 JP2022513507 A5 JP 2022513507A5
Authority
JP
Japan
Prior art keywords
cancer
sequence
composition according
nucleic acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513507A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067758 external-priority patent/WO2020132396A1/en
Publication of JP2022513507A publication Critical patent/JP2022513507A/ja
Publication of JP2022513507A5 publication Critical patent/JP2022513507A5/ja
Priority to JP2025023522A priority Critical patent/JP2025071138A/ja
Pending legal-status Critical Current

Links

JP2021535122A 2018-12-20 2019-12-20 ナノトランスポゾン組成物および使用方法 Pending JP2022513507A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025023522A JP2025071138A (ja) 2018-12-20 2025-02-17 ナノトランスポゾン組成物および使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862783133P 2018-12-20 2018-12-20
US62/783,133 2018-12-20
US201962815335P 2019-03-07 2019-03-07
US62/815,335 2019-03-07
US201962815845P 2019-03-08 2019-03-08
US62/815,845 2019-03-08
PCT/US2019/067758 WO2020132396A1 (en) 2018-12-20 2019-12-20 Nanotransposon compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025023522A Division JP2025071138A (ja) 2018-12-20 2025-02-17 ナノトランスポゾン組成物および使用方法

Publications (2)

Publication Number Publication Date
JP2022513507A JP2022513507A (ja) 2022-02-08
JP2022513507A5 true JP2022513507A5 (cg-RX-API-DMAC7.html) 2022-12-27

Family

ID=69469181

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535122A Pending JP2022513507A (ja) 2018-12-20 2019-12-20 ナノトランスポゾン組成物および使用方法
JP2025023522A Pending JP2025071138A (ja) 2018-12-20 2025-02-17 ナノトランスポゾン組成物および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025023522A Pending JP2025071138A (ja) 2018-12-20 2025-02-17 ナノトランスポゾン組成物および使用方法

Country Status (8)

Country Link
US (1) US20220042038A1 (cg-RX-API-DMAC7.html)
EP (1) EP3898993A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022513507A (cg-RX-API-DMAC7.html)
KR (1) KR20210105947A (cg-RX-API-DMAC7.html)
CN (1) CN113498439A (cg-RX-API-DMAC7.html)
AU (1) AU2019401282B2 (cg-RX-API-DMAC7.html)
CA (1) CA3124103A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020132396A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019240068B2 (en) * 2018-03-21 2025-03-13 Aldevron, L.L.C. Viral and non-viral nanoplasmid vectors with improved production
WO2020169673A1 (en) * 2019-02-19 2020-08-27 European Molecular Biology Laboratory Cell penetrating transposase
CN115135672A (zh) 2019-12-20 2022-09-30 波赛达治疗公司 抗muc1组合物和使用方法
WO2022182792A1 (en) 2021-02-23 2022-09-01 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
KR102602485B1 (ko) * 2021-07-09 2023-11-17 주식회사 네오젠티씨 트랜스포존 시스템 및 이의 용도
WO2023282730A1 (ko) * 2021-07-09 2023-01-12 주식회사 네오젠티씨 트랜스포존 시스템 및 이의 용도
AU2022360244A1 (en) 2021-10-04 2024-04-11 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
JP2025525583A (ja) * 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性dnaベクター
KR20250167670A (ko) 2023-04-05 2025-12-01 포세이다 테라퓨틱스, 인크. 초극소 역위 말단 반복(itr) 서열 및 그의 용도
WO2025160432A1 (en) 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Methods and compositions for enhancing in vivo persistence and potency of cell therapy
WO2025221789A1 (en) 2024-04-16 2025-10-23 Poseida Therapeutics, Inc. Compositions and methods for use in car/tcr cell therapies
WO2026080393A1 (en) 2024-10-07 2026-04-16 Poseida Therapeutics, Inc. Compositions and methods for use in car cell therapies
WO2026107088A1 (en) 2024-11-13 2026-05-21 Poseida Therapeutics, Inc. Dual car constructs and methods of use
WO2026107078A1 (en) 2024-11-13 2026-05-21 Poseida Therapeutics, Inc. Chimeric antigen receptor compositions and methods of use

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US4939666A (en) 1987-09-02 1990-07-03 Genex Corporation Incremental macromolecule construction methods
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2109945T3 (es) 1990-06-01 1998-02-01 Chiron Corp Composiciones y procedimientos para identificar moleculas biologicamente activas.
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
IE920562A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
HUT73101A (en) 1993-02-12 1996-06-28 Harvard College Method for regulating transcription of targeted genes and other biological events
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5549551A (en) 1994-12-22 1996-08-27 Advanced Cardiovascular Systems, Inc. Adjustable length balloon catheter
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6218185B1 (en) 1996-04-19 2001-04-17 The United States Of America As Represented By The Secretary Of Agriculture Piggybac transposon-based genetic transformation system for insects
US5827729A (en) 1996-04-23 1998-10-27 Advanced Tissue Sciences Diffusion gradient bioreactor and extracorporeal liver device using a three-dimensional liver tissue
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6835394B1 (en) 1999-12-14 2004-12-28 The Trustees Of The University Of Pennsylvania Polymersomes and related encapsulating membranes
US6962810B2 (en) 2000-10-31 2005-11-08 University Of Notre Dame Du Lac Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac
US7088011B2 (en) 2003-11-21 2006-08-08 Smith Raymond W Motor-generator system with a current control feedback loop
US9228180B2 (en) 2007-07-04 2016-01-05 Max-Delbruck-Centrum Fur Molekulare Medizin Polypeptide variants of sleeping beauty transposase
EP4733396A2 (en) 2009-02-26 2026-04-29 Poseida Therapeutics, Inc. Hyperactive piggybac transposases
US8808748B2 (en) 2010-04-20 2014-08-19 Vindico NanoBio Technology Inc. Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
US20140363496A1 (en) 2011-01-07 2014-12-11 Vindico NanoBio Technology Inc. Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors
ES2778033T3 (es) 2012-11-16 2020-08-07 Poseida Therapeutics Inc Enzimas específicas de sitio y métodos de uso
EP3019618B1 (en) * 2013-07-12 2018-10-31 University of South Alabama Minimal piggybac vectors for genome integration
US10927384B2 (en) 2014-04-09 2021-02-23 Dna Twopointo Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
SG10201808811QA (en) * 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
WO2015195798A1 (en) 2014-06-17 2015-12-23 Poseida Therapeutics, Inc. A method for directing proteins to specific loci in the genome and uses thereof
CA2952618A1 (en) 2014-06-17 2015-12-23 Poseida Therapeutics, Inc. Methods and compositions for in vivo non-covalent linking
JP7366518B2 (ja) * 2015-05-06 2023-10-23 ヤンセン バイオテツク,インコーポレーテツド 前立腺特異的膜抗原結合フィブロネクチンiii型ドメイン
JP2018521689A (ja) 2015-06-17 2018-08-09 ポセイダ セラピューティクス, インコーポレイテッド タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
US20170000743A1 (en) 2015-07-02 2017-01-05 Vindico NanoBio Technology Inc. Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
WO2017025447A1 (en) * 2015-08-10 2017-02-16 Curevac Ag Method of increasing the replication of a circular dna molecule
CN105154473B (zh) * 2015-09-30 2019-03-01 上海细胞治疗研究院 一种高效安全的转座子整合系统及其用途
CN108601951B (zh) * 2015-12-09 2022-11-22 金港医疗(澳大利亚)私人有限公司 用于治疗的免疫调节组合物
CA3004665C (en) * 2015-12-14 2021-08-24 GenomeFrontier Therapeutics, Inc. Transposon system, kit comprising the same, and uses thereof
EP3449004B1 (en) 2016-04-29 2021-02-24 Poseida Therapeutics, Inc. Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids
BR112019000683A2 (pt) * 2016-07-15 2019-04-24 Poseida Therapeutics Inc receptores de antígeno quiméricos e métodos para uso
WO2018014122A1 (en) * 2016-07-18 2018-01-25 Helix Biopharma Corp. Car immune cells directed to carcinoembryonic antigen related cell adhesion molecule 6 to treat cancer
WO2018068022A1 (en) 2016-10-06 2018-04-12 Poseida Therapeutics, Inc. Inducible caspases and methods for use
EP3559035A1 (en) * 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
US11015047B1 (en) 2017-09-05 2021-05-25 Toray Industries, Inc. Moldings of fiber-reinforced thermoplastic resin
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
WO2019126589A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Micelles for complexation and delivery of proteins and nucleic acids
BR112020018049A2 (pt) * 2018-03-07 2020-12-29 Poseida Therapeutics, Inc. Composições de cartirina e métodos para uso
AU2019240068B2 (en) * 2018-03-21 2025-03-13 Aldevron, L.L.C. Viral and non-viral nanoplasmid vectors with improved production
US20210107789A1 (en) 2018-05-23 2021-04-15 The Research Foundation For Microbial Diseases Of Osaka University Aluminum phosphate compound

Similar Documents

Publication Publication Date Title
Shabgah et al. CXC chemokine ligand 16: a Swiss army knife chemokine in cancer
JP2024074801A5 (cg-RX-API-DMAC7.html)
Balli et al. Foxm1 transcription factor is required for lung fibrosis and epithelial‐to‐mesenchymal transition
Greenbaum et al. Chimeric antigen receptor T-cells in B-acute lymphoblastic leukemia: state of the art and future directions
WO2021147121A1 (zh) 修饰的免疫细胞及其应用
Tamai et al. 11q23/MLL acute leukemia: update of clinical aspects
ES2848478T3 (es) Receptores quiméricos para antígenos y usos de estos
JP2021502070A5 (cg-RX-API-DMAC7.html)
CN110650975A (zh) 双顺反子嵌合抗原受体及其用途
JP2025071138A (ja) ナノトランスポゾン組成物および使用方法
Yan et al. AML chemoresistance: the role of mutant TP53 subclonal expansion and therapy strategy
RU2011146048A (ru) Сконструированные мезенхимальные стволовые клетки и способ их применения для лечения опухолей
BR112021008082A2 (pt) terapia contra o câncer com células imunitárias anti-liv1
JP2021512123A5 (cg-RX-API-DMAC7.html)
JP2020522244A5 (cg-RX-API-DMAC7.html)
JP2015507625A5 (cg-RX-API-DMAC7.html)
JP2023528415A5 (cg-RX-API-DMAC7.html)
JP2024528052A5 (cg-RX-API-DMAC7.html)
Prima et al. Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t (1; 19)(q23; p13. 3) in acute lymphoblastic leukemia
Sun et al. RETRACTED ARTICLE: Long Non-Coding RNA LEF1-AS1 Promotes Migration, Invasion and Metastasis of Colon Cancer Cells Through miR-30-5p/SOX9 Axis
JP2023510121A5 (cg-RX-API-DMAC7.html)
CN112921072A (zh) 一种脑转移相关基因的CRISPR/Cas9文库高通量筛选方法
Zhao et al. Effects of shRNA-silenced livin and survivin on lung cancer cell proliferation and apoptosis
JP2023515821A5 (cg-RX-API-DMAC7.html)
US20240401085A1 (en) Transposon compositions and methods of use thereof